Cat. No.: HY-N0589

Dehydrodiisoeugenol

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Dehydrodiisoeugenol is an orally active anti-inflammatory and anti-tumor agent. Dehydrodiisoeugenol inhibits the proliferation of colorectal cancer cells, and induces apoptosis, autophagy, endoplasmic reticulum stress and cell cycle arrest. Dehydrodiisoeugenol also exerts anti-inflammatory effects by inhibiting the activation of NF-κB and the expression of COX-2. Dehydrodiisoeugenol can be used in the research related to colorectal cancer, inflammatory diseases and ulcerative colitis.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 2680-81-1
Formula: C₂₀H₂₂O₄
Molecular Weight:326.39

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Dehydrodiisoeugenol Chemical Structure

CAS No.: 2680-81-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

NF-κB; COX-2^[2]

All NF-κB Isoforms :

All COX Isoforms :

All NO Synthase Isoforms :

All JNK Isoforms :

All p38 MAPK Isoforms :

All CDK Isoforms :

All NOD-like Receptor (NLR) Isoforms :

In Vitro

Dehydrodiisoeugenol (0.001-1000 μM; 24-72 h) inhibits the viability of human colorectal cancer HCT 116 and SW620 cells in a time- and dose-dependent manner, with IC₅₀ values of 54.32 μM and 46.74 μM respectively after 48 h of treatment, and exerts weak inhibitory effects on the viability of normal human colonic epithelial NCM460 cells^[1].
Dehydrodiisoeugenol (20-60 μM; 48 h) reduces the self-renewal and colony-forming capacities of human colorectal cancer HCT 116 and SW620 cells, and induces cell cycle arrest, autophagy and endoplasmic reticulum stress^[1].
Dehydrodiisoeugenol (0.1-10 μM; 3.5-6.5 h) potently inhibits LPS (HY-D1056)-induced COX-2 expression in RAW264.7 mouse macrophages without affecting the expression of constitutive COX-1^[2].
Dehydrodiisoeugenol (0.1 μM; 1 h) inhibits LPS-induced, phosphorylation-dependent IκB-α proteolysis in RAW264.7 mouse macrophages^[2].
Dehydrodiisoeugenol (0.1 μM; 6.5 h) inhibits the transcriptional activity of NF-κB in LPS-stimulated RAW264.7 mouse macrophages^[2].
Dehydrodiisoeugenol (2.5-10 μM; 24 h) inhibits the production of NO and PGE₂, the expression of iNOS, COX2 and NOD2, and the activation of MAPK and NF-κB pathways in RAW264.7 macrophages stimulated by LPS/IFNγ^[3].
Dehydrodiisoeugenol (20-40 μM; 0-10 days) inhibits colony formation and proliferation of HCT116 colorectal cancer cells, and induces apoptosis, autophagy and cell cycle arrest^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

human colorectal cancer cell lines HCT 116, SW620; normal human colon epithelial cell NCM460
Concentration:

0.001, 0.01, 0.1, 1, 10, 20, 40, 60, 80, 100, 125, and 1000 μM
Incubation Time:

24 h, 48 h, 72 h
Result:

Inhibited cell viability in a time- and dose-dependent manner in HCT 116 and SW620 cells.
Showed significantly higher IC50 for normal NCM460 cells than colorectal cancer cell lines.

Western Blot Analysis^[1]

Cell Line:

human colorectal cancer cell lines HCT 116, SW620
Concentration:

20, 40 and 60 μM
Incubation Time:

0 h, 12 h, 24 h, 48 h
Result:

Significantly increased the expression of p21 protein in a dose- and time-dependent manner.
Significantly reduced the expression of CDK2, CDK4, Cyclin D1, Cyclin E1, and Cyclin E2 proteins in a dose- and time-dependent manner.

Western Blot Analysis^[1]

Cell Line:

human colorectal cancer cell lines HCT 116, SW620
Concentration:

20, 40 amd 60 μM
Incubation Time:

48 h
Result:

Upregulated the expression of LC3B-II, ATG7, and p62 proteins in a dose-dependent manner.\n
Upregulated the expression of BiP, Ero1-Lα, PERK, p-eIF2α, IRE1α, XBP-1s, and CHOP proteins in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:

human colorectal cancer cell lines HCT 116, SW620
Concentration:

60 μM (48 h; 6 h for EBSS co-treatment)
Incubation Time:

6 h, 48 h
Result:

Reduced LC3B-II levels when co-treated with 3-MA compared to DEH alone. Did not cause a further increase in LC3B-II levels when co-treated with CQ or Baf A1 compared to DEH alone.

Western Blot Analysis^[2]

Cell Line:

RAW264.7 murine macrophages
Concentration:

0.1 μM
Incubation Time:

30 min pre-incubation, followed by 30 min LPS stimulation
Result:

Significantly inhibited LPS-stimulated phosphorylation of IκB-α.
Prevented LPS-induced degradation of total IκB-α protein.

Western Blot Analysis^[3]

Cell Line:

LPS/IFNγ-stimulated RAW264.7 macrophages
Concentration:

2.5, 5 and 10 μM
Incubation Time:

24 h
Result:

Significantly inhibited the expression of iNOS and COX2, with the most pronounced effect at 10 μM.
Inhibited the phosphorylation of IKKα/β and IκBα at 5 and 10 μM.
Inhibited IκBα degradation and NF-κB p65 nuclear translocation at 10 μM.
Significantly inhibited the phosphorylation of ERK, JNK, and p38 at 2.5, 5, and 10 μM.

In Vivo

Dehydrodiisoeugenol (40 mg/kg; i.p.; once every other day; 2 weeks) significantly inhibits colorectal cancer tumor growth in mouse CDX and PDX models, reduces tumor cell proliferation, induces ER stress and alters autophagy signaling pathways, and exhibits low toxicity in mice^[1].
Dehydrodiisoeugenol (5-20 mg/kg; i.g.; once daily; for 8 days) dose-dependently ameliorates DSS (HY-116282C)-induced ulcerative colitis in BALB/c mice by alleviating intestinal inflammation, restoring barrier function, and inhibiting NOD2 expression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/SCID (5-week-old female)^[1]
Dosage:

40 mg/kg
Administration:

i.p.; once every other day; 2 weeks
Result:

Significantly reduced tumor volume in HCT 116, SW620, and PDX xenograft models relative to controls.
Significantly reduced the percentage of Ki67-positive cells (cell proliferation marker) in tumor tissues relative to controls.
Significantly upregulated expression of ER stress-related proteins (BiP, PERK, IRE1α) and autophagy-related proteins (LC3B-II, p62) in harvested tumors relative to controls.
Showed no significant changes in mouse body weight, and H&E staining of heart, liver, spleen, lung, and kidney tissue revealed no pathological abnormalities indicative of toxicity.

Animal Model:

BALB/c (male, 6-8 weeks old, 20-22 g, ulcerative colitis model via 3.5% DSS gavage)^[3]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

p.o.; daily; 8 days
Result:

Significantly increased mouse body weight and colon length compared to the DSS model group.\n
Dose-dependently reduced colon mucosal damage, edema, and inflammatory cell infiltration, with partial recovery of goblet cells and crypts.
Significantly restored colonic ZO-1 and Occludin protein expression at 20 mg/kg to improve intestinal barrier function.\n
Dose-dependently significantly reduced colon MPO levels and serum TNF-α, IL-6, and IL-1β levels.
Significantly reduced colonic NOD2 protein expression at 10 mg/kg and 20 mg/kg.

Chemical Information

CAS No. 2680-81-1
Appearance Solid
Molecular Weight 326.39
Formula C₂₀H₂₂O₄
Color White to off-white
SMILES

OC1=CC=C(C2OC3=C(OC)C=C(/C=C/C)C=C3C2C)C=C1OC
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
- Phenols
- Monophenols
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All Cell Proliferation/Viability AssayWBHistological Imaging/StainingFlow CytometryELISA

Sort by:

Journal Impact Factor

Mol Med

Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword. [Abstract]

2025 Jun 5;31(1):221. PMID: 40468178

Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221. [Abstract]

The CCK-8 assay to determine the cell viability of LPS (0.5 µg/ml)/IFNγ (10ng/ml) stimulated RAW264.7 cells treated with different concentration of Dehydrodiisoeugenol (DEH) (0.5, 1, 2, 4, 8, 10, 20 μM) or Curcumin (5µM).

Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221. [Abstract]

Western blotting analysis of iNOS and COX2 protein expression in RAW264.7 cells treated with different concentrations of Dehydrodiisoeugenol (DEH) (2.5, 5, 10 μM) or curcumin (5 µM) following LPS/IFNγ stimulation.

Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221. [Abstract]

Apply the HE staining method to detect the effects of Dehydrodiisoeugenol (DEH) (40 mg/kg) or an equivalent solvent gastric lavage on the nude mouse xenografts.

Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221. [Abstract]

Flow cytometry was used to detect apoptosis in the cells. HCT116 cells were treated with Dehydrodiisoeugenol (DEH) (20 µM, 40 µM) for 24 h.

Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221. [Abstract]

ELISA was used to measure the expression levels of MPO, IL-1β, TNF-α, and IL-6 treated with Dehydrodiisoeugenol (DEH) (5, 10, 20 mg/kg, i.g.).
Lipids Health Dis

Dehydrodiisoeugenol alleviates palmitate-induced mitochondrial dysfunction in human vascular smooth muscle cells through the activation of SIRT1-mediated Drp1 deacetylation. [Abstract]

2025 May 24;24(1):187. PMID: 40413480
Front Cell Dev Biol

Licarin-B Exhibits Activity Against the Toxoplasma gondii RH Strain by Damaging Mitochondria and Activating Autophagy. [Abstract]

2021 Jun 11:9:684393. PMID: 34179016
Cell Biochem Funct

Dehydrodiisoeugenol Alleviates Sodium Palmitate-Induced Mitochondrial Dysfunction and Activates Autophagy in VSMCs via the SIRT1/Nrf2 Axis. [Abstract]

2025 Apr;43(4):e70074. PMID: 40231935

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (306.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0638 mL

15.3191 mL

30.6382 mL

5 mM

0.6128 mL

3.0638 mL

6.1276 mL

10 mM

0.3064 mL

1.5319 mL

3.0638 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li C, et al. Dehydrodiisoeugenol inhibits colorectal cancer growth by endoplasmic reticulum stress-induced autophagic pathways. J Exp Clin Cancer Res. 2021;40(1):125. Published 2021 Apr 10. [Content Brief]

[2]. Murakami Y, et al. Dehydrodiisoeugenol, an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages. Arch Biochem Biophys. 2005;434(2):326-332. [Content Brief]

[3]. Yi F, et al. Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword. Mol Med. 2025;31(1):221. Published 2025 Jun 5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0638 mL	15.3191 mL	30.6382 mL	76.5955 mL
	5 mM	0.6128 mL	3.0638 mL	6.1276 mL	15.3191 mL
	10 mM	0.3064 mL	1.5319 mL	3.0638 mL	7.6595 mL
	15 mM	0.2043 mL	1.0213 mL	2.0425 mL	5.1064 mL
	20 mM	0.1532 mL	0.7660 mL	1.5319 mL	3.8298 mL
	25 mM	0.1226 mL	0.6128 mL	1.2255 mL	3.0638 mL
	30 mM	0.1021 mL	0.5106 mL	1.0213 mL	2.5532 mL
	40 mM	0.0766 mL	0.3830 mL	0.7660 mL	1.9149 mL
	50 mM	0.0613 mL	0.3064 mL	0.6128 mL	1.5319 mL
	60 mM	0.0511 mL	0.2553 mL	0.5106 mL	1.2766 mL
	80 mM	0.0383 mL	0.1915 mL	0.3830 mL	0.9574 mL
	100 mM	0.0306 mL	0.1532 mL	0.3064 mL	0.7660 mL

Keywords

Dehydrodiisoeugenol

4 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Dehydrodiisoeugenol

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Dehydrodiisoeugenol

All NF-κB Isoforms

All COX Isoforms